|
|
Chen XC et al / Acta Pharmacol Sin 2005 Feb; 26 (2): 56-62 |
|
|
|
Full-length article
Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress1
Xiao-chun CHEN2, Yi-can ZHOU, Ying CHEN, Yuan-gui ZHU, Fang
FANG, Li-min CHEN
Fujian Institute of Geriatrics, Union Hospital, Fujian Medical University,
Fuzhou 350001, China
1 Project supported by Major Funding from the Fujian
Department of Education (JA02219) and Key Grant from the Fujian Science and
Technology Bureau (2001Z037).
2 Correspondence to Prof. Xiao-chun CHEN. Phn 86-591-337-7664. Fax
86-591-337-0393. E-mail chenxc998@sohu.com
Received 2004-05-25 Accepted 2004-08-31
doi: 10.1111/j.1745-7254.2005.00019.x
Abstract
Aim: To investigate the effect of ginsenoside Rg1, an effective ingredient from ginsenoside, on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced substantia nigra neuron lesion. Methods: C57-BL mice were given MPTP to prepare Parkinson disease mice model. Different doses of Rg1 (5, 10, and 20 mg·kg-1·d-1) or N-acetylcystein (NAC) (300 mg·kg-1·d-1) were given 3 d prior to MPTP in the pretreatment groups. Glutathione (GSH) level and total superoxide dismutase (T-SOD) activity in substantia nigra were determined by spectrophoto-metry. Nissl staining, tyrosine hydroxylase immunostaining, and TUNEL labeling were used to observe the damage and apoptosis of nigral neurons. Western blot analysis was used to detect the phospho-JNK and phospho-c-Jun levels in midbrain homogenates. Results: Pretreatments of C57-BL mice with different doses of Rg1 or NAC were found to protect against MPTP-induced substantia nigra neurons loss. Rg1 or NAC prevented GSH reduction and T-SOD activation in substantia nigra, and attenuated the phosphorylations of JNK and c-Jun following MPTP treatment. Conclusion: The antioxidant property of Rg1 along with the blocking of JNK signaling cascade might contribute to the neuroprotective effect of ginsenoside Rg1 against MPTP.
Key words ginsenoside Rg1; N-acetylcystein; apoptosis; JNK mitogen-activated protein kinases; inbred C57BL mice
Extract
Note: Please read the
complete full text with Figures and Tables at
![]()
Introduction
The pathological hallmark of Parkinson disease (PD) is the loss of dopaminergic neurons in the substantia nigra (SN), which leads to the major clinical and pharmacological abnormalities that characterize the disease. Although the exact cause of neuronal loss is still unknown, current evidence points to the presence of ongoing oxidative stress and the generation of radical oxygen species (ROS) selectively in the pars compacta of substantia nigra (SNPC) of parkinsonian brains[1, 2]. Human postmortem studies also suggested that oxidative damage to lipids, proteins, and DNA occurred in the SNPC of PD patients[3-5]. The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is metabolized in the brain by monoamine oxidase-B to its toxic metabolite, 1-methyl-4-phenylpyridinium ion (MPP+), which is then selectively taken up into the dopaminergic neurons. MPP+ exerts its toxic effect in the dopaminergic neurons by inhibiting mitochondrial NADH dehydrogenase (NADH-DH)[6]. MPTP could induce PD-like symptoms in humans and primates and causes degeneration of dopaminergic neurons in several animal species. The MPTP animal model is the ideal PD model for studying the pathogenesis of the disease.
The c-Jun NH2-terminal kinase (JNK) signaling cascade has been implicated as a mediator of MPTP-induced apoptotic neuronal death[7,8]. Oxidative stress is an important activator of the JNK signaling cascade. In differentiated PC12 cells and cultured sympathetic neurons, increases in oxidative stress induced by antisense inactivation of superoxide dismutase led to increased JNK activity[9].
Current treatments of PD are symptomatic and lack neuroprotective effect. Antioxidants have been focused on as candidates for the future treatment of PD. Ginsenoside Rg1, one of the active ingredients of ginseng, has potential neurotrophic and neuroprotective effects[10]. In our previous study, we found Rg1 could protect substantia nigra neurons against MPTP-induced apoptosis[11], and in a in vitro study we revealed that Rg1 could suppress intracellular oxidative stress to prevent PC12 cells from dopamine-induced apoptosis[12]. The aim of the current study is to further investigate whether Rg1 could suppress oxidative stress and block the activation of the JNK signaling cascade, and therefore protects dopaminergic neurons from apoptosis in an MPTP animal model. One antioxidant N-acetylcystein, which has been proved to protect against MPTP-induced substantia nigra neurons loss[13], was used as a positive contrast in this study.
Materials and methods
Animals and treatment
Male C57-BL mice weighing 18-22 g were divided into
six groups (n=8). MPTP (Sigma, St Louis, MO, USA) was dissolved in saline
at concentrations of 4 g/L. Ginsenoside Rg1 (purity >98 %), obtained from the
Department of Organic Chemistry of Norman Bethune Medical University (Changchun,
Jilin, China), was also dissolved in saline at concentrations of 1 g/L. Model
animals were injected subcutaneously with saline for 3 d, followed by injection
(subcutaneously) of MPTP (30
mg,kg-1,d-1) for 5 consecutive days. Three preventive
groups were injected (ip) with Rg1 (5 mg,kg-1,d-1, 10
mg,kg-1,d-1, 20
mg,kg-1,d-1). Positive contrast group was injected (sc)
with NAC (Jingke, Beijing, China, 300.0 mg,kg-1,d-1) for 8
days, and from the fourth day both Rg1 preventive groups and the positive
contrast group were received injection (sc) of MPTP (30 mg,kg-1,d-1,
2 h after Rg1 or NAC injection) for 5 consecutive days. The control group
received saline only. The animals were killed 24 h after the last injection. The
mice were anaesthetized with euthanal and perfused transcardially with ice-cold
saline prior to decapitation. The midbrain containing the substantia nigra was
dissected, and quickly frozen at -80 ºC until ready for later analysis. For
immunohistochemistry analysis, the midbrain was fixated in 4 % formal-dehydum
polymerisatum-PB and imbedded in paraffin. Serial 5-µm-thick sections were cut
transversely from the middle of the midbrain.
Spectrophotometry Substantia nigra were homogenized with 0.01 mol/L Tris-HCl (pH 7.4) consisting of 0.01 mol/L sucrose and 0.1 mmol/L EDTA, followed by centrifugation at 4000〜g for 15 min. The supernatant was saved and analyzed. The dithio-binitrobenzoic acid method and xanthine/xanthine oxidase method were used to test glutathione (GSH) level and total superoxide dismutase (T-SOD) activity. Reaction product was determined by spectrophotometry. Test Kits were purchased from Jian Cheng Bioengineering Institute (Nanjing, China).
TUNEL Deparaffinized and hydrated sections were incubated with proteinase K (20 mg/L in 10 mmol/L Tris/HCl, pH=7.4-8.0) for 30 min at 37 ºC, then incubated with TdT reaction mixture and AP-conjugated anti-fluorescein antibody (TUNEL detection kit, BM, Germany) for 1 h at 37 ºC. Finally sections were visualized with NBT-BCIP. The nuclei of positive cells were stained blue-black.
Nissl staining Paraffin sections were deparaffinized and hydrated, stained with methylene blue buffer for 10 min and then immersed into acetic acid buffer for 2 min.
Immunohistochemistry Paraffin sections were deparaffinized and hydrated, then incubated with a goat anti-mouse TH polyclonal antibody (1:40 dilution in 0.01 mmol/L phosphate buffer saline, pH 7.4) at 4 ºC overnight. Slides were then incubated with a biotinylated rabbit anti-goat IgG and SABC-reagent (SABC kit, BOSTER, Wuhan, Hubei, China), respectively for 30 min at 37 ºC. At last, sections were stained with diaminobenzidine (DAB). Hemotoxylin was used to counterstain nuclei for one minute.
Western blot analysis Substantia nigra was homogenized (50 g/L) in lysis buffer (10 mmol/L Tris, 50 mmol/L NaCl, 0.03 µmol/L sodium pyrophosphate, 50 mmol/L sodium fluoride, and 1% Triton X-100) containing 1 mmol/L phenylmethylsulfonyl fluoride, 20 mg/L aprotinin, and 1 mmol/L sodium vanadate[14]. After homogenization, samples were centrifuged at 15 000〜g for 15 min. The supernatants were taken for further analysis. Protein concentration was determined by the Bradford method[15]. Approxiamately 10 µg of total protein was separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. The membranes were probed with polyclonal anti-p-JNK1/2 or anti-p-c-Jun rabbit antibody (Cell Signaling, Beverly, MA, USA). Immunoreactive bands were visualized by the addition of horseradish peroxidase-conjugated antibodies against rabbit Fab and chemiluminescent substrates (Pierce, Rockford, IL, USA), according to the manufacturer's instruction.
Image analysis The numbers of Nissl, TH, TUNEL-positive neurons in full microscopic fields of SN were counted with a digital medical image analysis system (Motic, Beijing, China). Three tissue sections per animal were counted for each index.
Data analysis Data were expressed as means\SEM. TUNEL-positive cells were calculated as: [TUNEL-positive cells/(TUNEL-positive cells+Nissl staining cells)]〜100%. For statistical evaluation one-way analysis of variance (ANOVA) was employed. Student Newman Keuls test was performed when variance was equal, and Games-Howell test was performed when variance was not equal. Pearson correlation analysis was also carried out to some indices. Statistical difference was considered to be significant only if P<0.05.
Results
Effect of ginsenoside Rg1 on MPTP-induced
apoptosis of substantia nigra neurons
MPTP clearly had a detrimental effect on dopaminergic neurons. Treatment with
MPTP decreased the numbers of TH-positive and Nissl-positive neurons and
increased the percent of TUNEL-positive neurons in SN. Pretreatment with
ginsenoside Rg1 or NAC significantly ameliorated the neuronal loss and apoptosis
induced by MPTP (P<0.01) (Figure 1-3). Rg1 at 10 mg/kg showed the best
protective effect among all the doses but made no significant difference (P>
0.05) at 5 mg/kg and 20 mg/kg, which suggested that the effect of ginsenoside
Rg1 might have an optimal dose range. There was no significant difference
between NAC and Rg1 (10 mg/kg) treatment group.
Effect of ginsenoside Rg1 on GSH level and
T-SOD activity in SN Decreased GSH level and increased T-SOD activity were
detected in the substantia nigra of MPTP-treated mice. Both changes were
attenuated by pre-administration with ginsenoside Rg1 or NAC (Table 1, P<0.01).
Better preventive effects were observed at doses of 10 and 20
mg/kg than at 5 mg/kg among Rg1 treated groups, but there was no significant
difference among 10 mg/kg, 20 mg/kg of Rg1, and NAC (300.0 mg/kg). Correlation
analysis showed a positive correlation between the positive neuron ratio of TH
and the GSH level (r=0.885, P<0.01), and negative correlation
between the positive neuron ratio of TH and the T-SOD activity (r=-0.882,
P<0.01). These results indicate that enhanced oxidative stress was
involved in the neurotoxicity of MPTP; and suitable doses of Rg1 could attenuate
the oxidative stress induced by MPTP, while overdoses of Rg1 did not show better
preventive effect.
Influence of MPTP-induced JNK and c-Jun
phosphorylation by ginsenoside Rg1 MPTP treatment increased the levels of
p46 and p54 phospho-JNK protein, as compared with the control. Preadministration
of Rg1 or NAC partially attenuated the MPTP-mediated elevation in phospho-JNK
and phospho-c-Jun levels in midbrain homogenates. A 10 mg/kg dose of Rg1 showed
the greatest inhibition as did NAC, but the weak inhibition was observed at the
dose of 20 mg/kg. These results suggested that Rg1 attenuated MPTP-induced
phosphorylation of JNK and
c-Jun, but a higher dosage was detrimental.
Discussion
Ginseng has been used in traditional Chinese medicine to enhance stamina and capacity to deal with fatigue and physical stress for thousands of years. Ginsenoside Rg1 is one of the active ingredients of ginseng. Previous in vitro studies showed that Rg1 could save cell from oxidative stress induced-apoptosis[16]. In the current study, we observed that TH-positive neurons loss in SN caused by MPTP could be attenuated by Rg1 or NAC pretreatment; the result showed the neuronal protective effect of ginsenoside Rg1 against MPTP. Our study also revealed the neuroprotective mechanisms of Rg1 in preventing MPTP-induced loss of dopaminergic neurons in SN. The neurotoxin of MPTP is dependent on the inhibition of Complex I in the mitochondrial respiratory chain by MPP+, subsequently followed by ATP depletion and increased production of ROS[17], eventually leads to the cell death. As one of the most important antioxidant molecule, GSH could clear H2O2 and prevent its reaction with iron to form the highly reactive OH- radical in the Fenton reaction. Following MPTP treatment, GSH was consumed and its level dropped[18,19]. We also observed the activity of T-SOD (including Cu/Zn-SOD and Mn-SOD), another important radical scavenger, was elevated in SN of MPTP treated mice; this change corresponded with those observed in PD patients[20-22]. NAC is a free radical oxygen scavenger. Furthermore, it can be converted into cysteine after entering cells, and is an important substrate for GSH production. In our current study, pretreatment with NAC could attenuate the loss of GSH and the increased activity of T-SOD following MPTP treatment, same changes were observed among Rg1 pretreatment groups. We found that the antioxidative effect of Rg1 had an optimal dose of 10 mg/kg, this dosage of Rg1 showed the similar effect as NAC, but there was no improvement beyond this dose. The results demonstrated that Rg1 possessed the same antioxidant property as NAC.
There has been no direct evidence indicating
that Rg1 could scavenge radical by itself, therefore we tried to investigate
whether Rg1 act as an antioxidant through mediator. In our previous study, we
found the protective effect of Rg1 against MPTP-induced nigral neurons apoptosis
was related to enhancing Bcl-2 expression and reducing iNOS expression[11].
Bcl-2 is an anti-apoptotic protein located in the outer mitochondrial membrane,
nuclear membrane and endoplasmic reticulum membrane. Bcl-2 participates in the
regulation of cell death through multiple mechanisms, one of which regulates the
steady state of cellular ROS levels. This can be achieved either by modulating
their production, usually by the mitochondria, or by affecting the antioxidant
capacity of the cells. In vitro and in vivo studies provided
evidences that Bcl-2 could attenuate cell injuries caused by oxidative stress.
Bcl-2 could protect against the increased level of ROS caused by dopamine
metabolism in PC12
cells[23]. Transfection with Bcl-2 provided the PC12 cells with
marked protection against dopamine-induced apoptosis and inhibited dopamine
oxidation to dopamine-melanin[24]. Further studies demonstrated
enhanced oxidative stress and susceptibility to oxidants in the brains of
Bcl-2-deficient
mice[25]. Our previous study showed that Rg1 could prevent the
decrease of Bcl-2-positive cell numbers following MPTP treatment, so this might
contribute to the antioxidant property of Rg1.
Another important protein involved in oxidative stress is nitric oxide synthase (NOS), of which three isoforms have been described: neuronal NOS (nNOS) and endothelial NOS are calcium-calmodulin-dependent enzymes, while inducible NOS (iNOS) activity is independent of intracellular calcium levels. Nitric oxide (NO), an important free radical generated by NOS, can react with superoxide radicals to form the oxidizing agents peroxynitrite (ONOO-) and OH- [26], and eventually induce DNA strand breakage and apoptosis[27]. Numerous experimental studies have shown that iNOS play an important role in MPTP-induced dopaminergic neuron injury or in PD patients[28,29], it is in agreement with our previous observation that MPTP increased the numbers of iNOS-positive cells. Therefore, changes of Bcl-2 and iNOS expressions could play important roles in the antioxidative effect of Rg1, this could explain the antioxidant property of Rg1. However, the exact pathway leading to the changes of Bcl-2 and iNOS expression in SN is still unclear.
The JNK signaling cascade is a main pathway that mediates the neurotoxicity of MPTP[14], CEP-1347/KT-7515, an inhibitor of JNK activation, can attenuate MPTP-induced nigrostriatal dopaminergic degeneration[7]. Transgenic mice expressing the JNK binding domain (JBD) of JNK interacting protein 1 could resist the neurotoxicity of MPTP[8]. Oxidative stress is an important activator of the JNK signaling cascade. In differentiated PC12 cells and cultured sympathetic neurons, oxidative stress induced by antisence inactivation of superoxide dismutase increased JNK activity[9]. In our previous study, we observed that JNK pathway was activated after the exposure of SHSY5Y cells to the mitochondrial complex I inhibitor MPP+, Rg1 could attenuate the elevation of ROS and reduce the JNK activation after MPP+ treatment[30]. In the present in vivo study, we also found that pretreatment with Rg1 or NAC could attenuate the elevated phosphorylation of JNK and c-Jun induced by MPTP in SN. The dose of 10 mg/kg of Rg1 showed better effect than dose of 5 mg/kg and 20 mg/kg. There was no significant difference between NAC and 10 mg/kg Rg1, but it is a puzzle why 20 mg/kg Rg1 had weaker inhibition than 10 mg/kg Rg1. The toxicity of higher doses of Rg1 could compromise its ability as a radical scavenger. However, this change is associated with the loss of dopaminergic neurons at different Rg1 doses. This results confirms previous studies that JNK signaling cascade play an important role in dopaminergic neuron apoptosis induced by MPTP, and appropriate dose of Rg1 could attenuate the MTPT induced activation of JNK signaling cascade. It requires further study to find out whether Rg1 influences JNK pathway through mechanisms other than antioxidation.
In conclusion, the present study indicates that pretreatment with certain doses of Rg1 could reduce the loss of dopaminergic neurons caused by MPTP in SN. The neuroprotective effects of Rg1 are potentially due to its antioxidant property that involves Bcl-2 and iNOS, and its inhibitory effect on JNK signaling cascade activation. Further studies will be carried out to evaluate whether ginsenoside Rg1, an important ingredient of ginsenoside, could benefit as a future preventive and therapeutic drug of PD.
References